Working closely with partners in Public Health, STChealth continues to monitor and respond to needs for data and updated guidance.
In early August, FDA issued an emergency use authorization for intradermal injection of JYNNEOS against Monkeypox for adults over the age of 18 years old. STChealth, Vaccine Intelligence experts for over 34 years, responded rapidly to changing organizational needs. Working in direct partnership with State Immunization Programs, STChealth altered inventory management to ensure tracking and reporting of these doses was standardized across STChealth registry systems. The goal is to help State Health Departments respond effectively to outbreaks by providing real-time population health insights and vaccine inventory intelligence.
“As Monkeypox continues to spread, the need for real-time data grows. Reporting and inventory tracking challenges are being quickly addressed by STChealth’s experts issuing updated guidance and ensuring our partner States are well positioned to succeed,” said STChealth Chief Scientific Officer, Dr. Kyle Freese.
As the situation with Monkeypox progresses, STChealth will continue to partner with States and pharmacy, as needed, to provide vaccine intelligence and relevant guidance based on best practices.
STChealth’s mission is to eradicate vaccine preventable disease and empower individuals through our innovative technology and service solutions. We deliver on our mission through passion and innovation, through teamwork and inclusion, through superior client service and products, and a relentless pursuit of the next ”big idea” that will advance immunization intelligence. Starting with developing the first Immunization Information System (IIS) and over 33 years of experience in the immunization ecosystem, STChealth is positioned today to support more than 1/3 of COVID-19 vaccinations reported in the U.S. through our network of over 54,000 Providers and Pharmacy Partners. More information can be found at www.STChealth.com